更汀芦单抗
化合物
更汀芦单抗（INN：Gantenerumab）是由罗氏制药公司开发的一种用于治疗阿尔茨海默病的单克隆抗体。[1][2]
_5CSZ.png) | |
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | β淀粉样蛋白（Aβ40/42） |
| 临床资料 | |
| ATC码 |
|
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 1043556-46-2  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6496H10072N1740O2024S42 |
| 摩尔质量 | 146.3 kg/mol (peptide) |
更汀芦单抗的III期临床试验因缺乏疗效而提前停止。[4]更汀芦单抗也在患有阿尔茨海默病高风险的年轻患者中进行了评估，[5]但经过五年的治疗，该药物对减缓患者认知能力下降几乎没有作用。[6]
参考资料
编辑- ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Gantenerumab (PDF). American Medical Association. [2023-12-06]. （原始内容存档 (PDF)于2012-02-20）.
- ^ International Nonproprietary Names for Pharmaceutical Substances (INN) (PDF). World Health Organization. （原始内容 (PDF)存档于2012-02-11）.
- ^ Panza F, Seripa D, Lozupone M, Solfrizzi V, Imbimbo BP, Barulli MR, et al. The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. Expert Opinion on Biological Therapy. January 2018, 18 (1): 25–35. PMID 29037101. S2CID 4795458. doi:10.1080/14712598.2018.1389885.
- ^ Ostrowitzki S, Lasser RA, Dorflinger E, Scheltens P, Barkhof F, Nikolcheva T, et al. A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. Alzheimer's Research & Therapy. December 2017, 9 (1): 95. PMC 5723032
. PMID 29221491. doi:10.1186/s13195-017-0318-y .
- ^ Clinical trial number NCT01760005 for "Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)" at ClinicalTrials.gov
- ^ Kolata G. An Alzheimer's Treatment Fails: 'We Don't Have Anything Now'. The New York Times. 10 February 2020 [2023-12-06]. （原始内容存档于2023-12-07）.
 | 这是一篇作用于神经系统的药品小作品。您可以通过编辑或修订扩充其内容。 |